Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01637259
Registration number
NCT01637259
Ethics application status
Date submitted
27/06/2012
Date registered
11/07/2012
Date last updated
20/01/2016
Titles & IDs
Public title
MARCH Renal Substudy
Query!
Scientific title
Maraviroc Switch Collaborative Study Renal Substudy
Query!
Secondary ID [1]
0
0
MARCH-Kirby renal
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MARCHrenal
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Proteinuria
0
0
Query!
HIV
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
Treatment: Drugs - Arm 2 boosted protease inhibitors and maraviroc
Treatment: Drugs - Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Active Comparator: NRTI + PI - arm 1
Active Comparator: PI + maraviroc - arm 2
Active Comparator: NRTI + maraviroc - arm 3
Treatment: Drugs: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
NRTI + PI
Treatment: Drugs: Arm 2 boosted protease inhibitors and maraviroc
PI + maraviroc
Treatment: Drugs: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
NRTI + maraviroc
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
changes in proteinuria and albuminuria between baseline and week 96
Query!
Assessment method [1]
0
0
To compare the change in protein and albumin excretion as measured by the urine PCR and ACR through the kidneys between the randomised and standard of care (control) arm of MARCH.
Query!
Timepoint [1]
0
0
96 weeks
Query!
Secondary outcome [1]
0
0
changes in renal tubular function between baseline and week 96
Query!
Assessment method [1]
0
0
To evaluate the following aspects of renal function at baseline and changes within and between study groups:
Tubular function defined as proximal tubular function; ascending thick loop of Henle; distal tubular function; volume and renal potassium handling;
Non-tubular function i.e. eGFR; Urine albumin:creatinine ratio;
Determine factors associated with renal dysfunction within the cohort e.g. demographics, HIV related, HIV-treatment related, co-morbidities, concomitant medication (such as ACE inhibitors and ARB; PI/r co-administered with TDF); TDF use;
Query!
Timepoint [1]
0
0
96 weeks
Query!
Eligibility
Key inclusion criteria
- Provision of written, informed consent for participation in the substudy
- Enrolled into the substudy either at or before the week 0 visit of the main study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
76
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
St. Vincent's Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
Brisbane Sexual Health and HIV Service - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
2010 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
4000 - Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Ciudad de Buenos Aires
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
Alberta
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Ontario
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Quebec
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Cologne
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Dusseldorf
Query!
Country [7]
0
0
Japan
Query!
State/province [7]
0
0
Nagoya
Query!
Country [8]
0
0
Mexico
Query!
State/province [8]
0
0
Tlalpan DF
Query!
Country [9]
0
0
Thailand
Query!
State/province [9]
0
0
Bangkok
Query!
Country [10]
0
0
United Kingdom
Query!
State/province [10]
0
0
Lothian
Query!
Country [11]
0
0
United Kingdom
Query!
State/province [11]
0
0
Sussex
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Kirby Institute
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV.
Antiretroviral therapy associated renal dysfunction has been predominantly described in terms
of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur
in the absence of significant reductions in eGFR. This substudy is an exploration of changes
in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and
safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase
inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with
stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of
combination antiretroviral therapy (cART).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01637259
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Waldo Belloso, MD
Query!
Address
0
0
Hospital Italiano de Buenos Aires
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01637259
Download to PDF